SOL 创新高,「Meme 链之王」能成为第三只现货 ETF?

Salmedix

company

About

It focuses on the treatment of hematologic malignancies or blood cancers.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$27.50M
Industries
Biotechnology,Health Care,Medical
Founded date
Nov 1, 2000
Number Of Employee
11 - 50
Operating Status
Active

Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers.

Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development.

Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$27.50M
Salmedix has raised a total of $27.50M in funding over 2 rounds. Their latest funding was raised on Jun 19, 2002 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 19, 2002 Series B $27.50M 2 Detail
Jan 1, 2001 Series A 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
Salmedix is funded by 2 investors. Biofrontier Partners and Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Biofrontier Partners Series B
Versant Ventures Series B